Side effect management algorithms for niraparib/abiraterone acetate in prostate cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Niraparib, a PARP1/2 inhibitor, is approved with abiraterone acetate (AA) plus prednisone/prednisolone (niraparib/AA+P) for BRCA-mutated metastatic castration resistant prostate cancer (mCRPC).
• Clinical practice may benefit from detailed guidance on managing side effects and dosing of this combination therapy.

Purpose of the Study:

• To develop management algorithms for common adverse events (AEs) associated with niraparib/AA+P in mCRPC.
• To provide practical guidance for Canadian clinicians on monitoring, treatment adjustments, and referrals for managing niraparib/AA+P-related AEs.

Main Methods:

• A panel of specialists designed management algorithms for anemia, thrombocytopenia, hypertension, and nausea.
• Algorithms are based on Health Canada-approved prescribing information for niraparib/AA+P.

Main Results:

• Panel recommendations generally align with the niraparib/AA+P product monograph.
• Common strategies for managing higher-grade AEs include temporary discontinuation of niraparib/AA+P and reintroduction at a lower dose.
• Hypertension management recommendations emphasize sequential anti-hypertensive medication trials before altering anti-cancer therapy.

Conclusions:

• The developed algorithms offer practical support for Canadian clinicians managing frequent AEs in mCRPC patients treated with niraparib/AA+P.
• These guidelines aim to optimize patient care and treatment adherence for this novel combination therapy.